Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
- 11/15/2024
|
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.
- 11/15/2024
|
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 09/17/2024
|
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
- SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 08/27/2024
|
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
- 08/17/2024
|
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.
- 08/16/2024
|
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product generic to Zoryve® Cream(roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
- 08/16/2024
|
Sol-Gel Technologies Announces Management Realignment
- NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that the Chief Executive Officer, Dr. Alon Seri-Levy, has recently advised the Sol-Gel Board of Directors of his desire to step down from his position as CEO and member of the Board.
- 07/15/2024
|
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.
- 05/20/2024
|
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million.
- 05/20/2024
|
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
- NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.
- 05/16/2024
|
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
- NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that Padagis Israel Pharmaceuticals Ltd (“Padagis”), Sol-Gel's collaboration partner, submitted a first-to-file Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream (roflumilast cream, 0.3%), indicated for the treatment of plaque psoriasis in patients six years of age and older.
- 04/01/2024
|
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
- An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved large-category dermatology products, TWYNEO® and EPSOLAY®, in the U.S, today announced financial results for the full year ended December 31st, 2023 and provided a corporate update.
- 03/13/2024
|
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
- NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened. SGT-610 is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.
- 11/30/2023
|
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
- NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced it will host a virtual KOL event on Wednesday, December 6, 2023 at 12:00 PM ET. To register, click here .
- 11/28/2023
|
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
- 11/09/2023
|
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
- 10/30/2023
|
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
- 08/30/2023
|
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.
- 08/10/2023
|
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- NESS ZIONA, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
- 08/10/2023
|
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.
- 05/12/2023
|
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright's Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.
- 03/20/2023
|
7 Biotech Stocks That Could Be the Next Big Thing
- While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.
- 03/15/2023
|
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
- Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.
- 03/10/2023
|
The Top 7 Penny Stocks to Invest in for the Long-Term
- Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investment.
- 02/23/2023
|
3 Generic Drug Stocks to Watch Amid Inflation Pressures
- The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
- 12/07/2022
|
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
- SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.
- 11/10/2022
|
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
- The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
- 09/09/2022
|
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
- SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022.
- 08/04/2022
|
SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates
- SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022.
- 05/13/2022
|
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
- SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
- 05/05/2022
|
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
- The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
- 05/02/2022
|
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
- NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Jefferies London Healthcare Conference, taking place in-person on November 16th and 17th, 2021.
- 11/09/2021
|
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
- NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th – 30th, 2021.
- 09/22/2021
|
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
- SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -75.00% and -71.55%, respectively, for the quarter ended June 2021.
- 08/04/2021
|
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
- NESS ZIONA, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the second quarter ended June 30, 2021 and provided an overview of recent corporate developments.
- 08/04/2021
|
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
- The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older. Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to release each of the active drug ingredients slowly.
- 07/27/2021
|
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
- NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Food and Drug Administration (FDA) has approved its first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO uses Sol-Gel's patented technology to entrap tretinoin, a retinoid, and benzoyl peroxide within silica-based microcapsules to stabilize tretinoin from being degraded by benzoyl peroxide and to slowly release each of the active drug ingredients over time to provide a favorable efficacy and safety profile. TWYNEO is patent protected until 2038. Sol-Gel has partnered with Galderma to commercialize TWYNEO in the U.S. Sol-Gel expects to receive a regulatory milestone payment in conjunction with this approval and retains the option to regain U.S. commercialization rights five years following first commercialization in the U.S.
- 07/27/2021
|
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
- NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
- 07/20/2021
|
Sol-Gel Announces Pipeline Update and Future Development Plans
- NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical data for SGT-510, its investigational topical roflumilast drug candidate and provided a corporate update.
- 06/28/2021
|
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
- NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world's largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States. Under these agreements, Galderma has an exclusive license to commercialize Sol-Gel's most advanced investigational drug products using Sol-Gel's
- 06/28/2021
|
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
- - Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ®
- 05/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
- New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sol-Gel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 04/28/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL
- NEW YORK, April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL) Such investors are advised to contact Robert S.
- 04/28/2021
|
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
- NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update regarding the U.S. Food and Drug Administration (FDA) approval process for EPSOLAY® (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults.
- 04/27/2021
|
SolGel Technologies Ltd. (SLGL) Moves 9.7% Higher: Will This Strength Last?
- SolGel Technologies Ltd. (SLGL) was a big mover last session on higher-than-average trading volume.
- 04/16/2021
|
SolGel Technologies Ltd. (SLGL) Stock Jumps 10.8%: Will It Continue to Soar?
- SolGel Technologies Ltd. (SLGL) witnessed a jump in share price last session on above-average trading volume.
- 03/11/2021
|
SolGel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
- SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 12.20% and -725.03%, respectively, for the quarter ended December 2020.
- 03/04/2021
|
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
- • Epsolay ® and Twyneo ® PDUFA goal date s set for April 26 , 2021 and August 1 , 2021 respectively
- 03/04/2021
|
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
- NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.
- 02/24/2021
|
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
- NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.
- 01/11/2021
|
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
- - PDUFA Goal Date Set for August 1, 2021
- 12/07/2020
|
Sol-Gel: Slow And Steady Topical Technology
- Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.
- 11/19/2020
|
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
- NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.
- 11/09/2020
|
